secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2022-05-11T23:59:59+00:00
Accession:  0000950170-22-009350
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya Q1 net loss $31.1M; TN-201 gets EU orphan designation, IND filings on track
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities of $213.5M at March 31; runway into H2 2023.
- Net loss of $31.1M ($0.75/sh) for Q1 2022; R&D expense $24.2M, G&A $7.0M.
- TN-201 received EU Orphan Medicinal Product designation for MYBPC3 HCM; IND expected H2 2022.
- Preclinical TN-401 data at Heart Rhythm 2022 showed restored heart function, reduced arrhythmia, increased survival; IND expected 2023.
- cGMP manufacturing facility in Union City expected operational H1 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000095017022009350/0000950170-22-009350-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000095017022009350/tnya-20220511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-009350

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer